IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial

Summary Background In a phase 2 study in patients with metastatic renal cell carcinoma, overall survival was associated with T-cell responses against IMA901, a vaccine consisting of ten tumour-associated peptides. In this phase 3 trial, we aimed to determine the clinical effect of adding IMA901 to s...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The lancet oncology 2016-11, Vol.17 (11), p.1599-1611
Hauptverfasser:	Rini, Brian I, Prof, Stenzl, Arnulf, Prof, Zdrojowy, Romauld, Prof, Kogan, Mikhail, Prof, Shkolnik, Mikhail, MD, Oudard, Stephane, Prof, Weikert, Steffen, Prof, Bracarda, Sergio, Prof, Crabb, Simon J, PhD, Bedke, Jens, Prof, Ludwig, Joerg, PhD, Maurer, Dominik, PhD, Mendrzyk, Regina, PhD, Wagner, Claudia, PhD, Mahr, Andrea, PhD, Fritsche, Jens, PhD, Weinschenk, Toni, PhD, Walter, Steffen, PhD, Kirner, Alexandra, PhD, Singh-Jasuja, Harpreet, PhD, Reinhardt, Carsten, MD, Eisen, Tim, FRCP
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antigens Cancer Cancer Vaccines - administration & dosage Cancer Vaccines - adverse effects Carcinoma, Renal Cell - mortality Carcinoma, Renal Cell - pathology Carcinoma, Renal Cell - therapy Clinical trials Cytokines Dendritic cells Female Hematology, Oncology and Palliative Medicine Humans Indoles - administration & dosage Indoles - adverse effects Indoles - therapeutic use Kidney Neoplasms - mortality Kidney Neoplasms - pathology Kidney Neoplasms - therapy Lymphocytes Male Metastasis Middle Aged Neoplasm Metastasis Peptides Pharmaceutical industry Pyrroles - administration & dosage Pyrroles - adverse effects Pyrroles - therapeutic use Sunitinib T cell receptors Vaccines
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!